For millions of people living with hypertension, the struggle is not just the diagnosis, but the defiance of the disease. Even with a strict regimen of anti-hypertensive medications, a significant portion of patients find their blood pressure remains stubbornly high, leaving them vulnerable to strokes, heart failure, and cognitive decline.
Now, a collaborative effort between researchers at the University of São Paulo in Brazil and the University of Auckland in Novel Zealand may have identified a new cause of high blood pressure rooted not in the heart or kidneys, but in a specific region of the brain. The study suggests that a cluster of neurons responsible for breathing control may be “misfiring,” triggering a cascade that constricts blood vessels and drives up systemic pressure.
This discovery, published in Circulation Research, points toward a neurogenic driver of hypertension. By isolating the lateral parafacial (pFL) region of the brain, scientists found that this area can act as a switch for blood vessel constriction, potentially explaining why traditional medications—which often target the heart or the renal system—fail in so many cases.
The Breathing-Blood Pressure Connection
The lateral parafacial region is primarily known for its role in respiratory control. It manages the forceful, deliberate exhalations we use when coughing, laughing, or pushing through a strenuous workout. Under normal conditions, these neurons help the body adapt its breathing to immediate physical demands.
However, the research team discovered that in hypertensive models, the pFL region does more than just regulate breath. It communicates with the sympathetic nervous system—the body’s “fight-or-flight” mechanism—to signal blood vessels to tighten. When these vessels constrict, the heart must pump harder to move blood through a narrower space, resulting in a spike in blood pressure.
To prove this link, the researchers used genetic engineering in rats to manually activate and deactivate pFL neurons. When they turned the pFL neurons “on,” they observed a corresponding rise in blood pressure. Conversely, when they inactivated the region, blood pressure levels returned to normal.
“We discovered that, in conditions of high blood pressure, the lateral parafacial region is activated and, when our team inactivated this region, blood pressure fell to normal levels,” says physiologist Julian Paton from the University of Auckland.
Addressing the ‘Neurogenic’ Gap in Treatment
The clinical implications of this finding are substantial. Current estimates suggest that around 40 percent of patients continue to have uncontrolled blood pressure despite taking medication. This suggests that for a large subset of the population, the driver of hypertension is not a failure of the cardiovascular system itself, but a signal coming from the brain.
The researchers note that approximately 50 percent of patients with hypertension exhibit a neurogenic component. By understanding the specific mechanisms—such as the pFL-driven sympatho-excitation—doctors may eventually be able to tailor treatments to the specific cause of a patient’s high blood pressure rather than relying on a one-size-fits-all pharmacological approach.
This mechanism also provides a biological explanation for the high correlation between sleep apnea and hypertension. In sleep apnea, breathing is interrupted, leading to low oxygen levels and a buildup of carbon dioxide ($text{CO}_2$). Because pFL neurons are specifically designed to fire in response to these chemical changes, the repetitive respiratory distress of sleep apnea may chronically overstimulate the pFL region, leading to permanent hypertension.
A Potential Pathway to Treatment
While the ability to “turn off” a brain region is effective in a lab setting, it is not a viable clinical treatment for humans. The blood-brain barrier—a protective membrane that prevents most toxins and drugs from entering the brain—makes it difficult to target specific neurons without causing widespread side effects.
To bypass this, the team is looking at the carotid bodies. These are small clusters of chemosensors located in the neck that monitor blood chemistry and send signals directly to the pFL region. By targeting these sensors outside the brain, the researchers believe they can “quench” the overactivity of the pFL region remotely.
The team is currently repurposing an existing drug to inhibit carotid body activity. If successful, this would allow patients to regulate their blood pressure without the need for invasive brain surgery or drugs that must penetrate the blood-brain barrier.
Summary of the pFL Hypertension Mechanism
| Stage | Biological Action | Result |
|---|---|---|
| Trigger | High $text{CO}_2$ or low $text{O}_2$ (e.g., sleep apnea) | pFL neurons are activated |
| Signal | pFL communicates with the brainstem | Sympathetic nervous system activation |
| Response | Peripheral blood vessels constrict | Increased systemic blood pressure |
| Proposed Fix | Targeting carotid body sensors | Inactivation of pFL and BP reduction |
The Road Ahead
It is important to maintain a cautious perspective: this research was conducted using animal models. While the circuitry in rats is remarkably similar to that in humans, the transition from lab success to clinical pharmacy is long and rigorous. Human trials will be necessary to confirm that the pFL region operates identically in people and that targeting the carotid bodies is both safe and effective.
Nonetheless, with nearly one-third of the global population affected by hypertension—a condition closely linked to heart disease and dementia—the urgency for new therapeutic strategies is high. The ability to treat the brain’s role in blood pressure could provide a lifeline for those for whom current medicine has failed.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The researchers are now moving toward further testing of the repurposed drug to determine its efficacy in suppressing carotid body activity. Further updates on the transition to human-centric studies are expected as the team progresses through the next phase of pharmacological testing.
Do you or a loved one struggle with uncontrolled blood pressure? We invite you to share your experiences or questions in the comments below.
